Alumis Inc.（股票代码：ALMS）今日盘中股价飙升167.51%，创下历史性涨幅。
这一剧烈波动源于公司宣布其口服TYK2抑制剂Envudeucitinib在治疗中重度斑块状银屑病的两项三期临床试验中均达到主要终点。试验数据显示，约65%的患者在24周治疗后实现皮肤症状改善90%以上，40%以上患者达到完全清除，疗效显著优于安慰剂及安进公司的口服药Otezla。
分析师指出，该药物通过阻断TYK2蛋白抑制过度免疫反应，其疗效接近注射类药物，有望成为同类最佳疗法。公司计划2026年下半年提交FDA申请，若获批将与百时美施贵宝的Sotyktu展开竞争。此次突破性数据显著提升了市场对Alumis商业化前景的预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.